<DOC>
	<DOCNO>NCT01327729</DOCNO>
	<brief_summary>The objective ass efficacy , dose , safety tolerance Y- shape pegylated interferon ( YPEG-IFNα-2a ) plus ribavirin Egyptian patient chronic hepatitis C prior treatment hepatitis C virus ( HCV ) . Methods : Randomized , Open-label trial , 3 parallel group ( 100 patient )</brief_summary>
	<brief_title>Y- Shaped Pegylated Interferon ( YPEG-IFNα-2a ) Plus Ribavirin Egyptian Patients With Untreated Chronic Hepatitis C</brief_title>
	<detailed_description>Methods : Randomized , Open-label trial , parallel group ( 100 patient ) . Treatment give 48 week ( positive HCV polymerase chain reaction ( PCR ) patient 24 week consider non responder ) follow-up 24 week . Total treatment follow-up duration : 72 week . Enrollment duration : 18 month . Total trial duration : 2 year 9 month , include trial analysis ( carry 6 month follow follow-up completion last patient ) . Total number patient : 300 . Precision around expect efficacy rate ( 45 % intention-to-treat analysis ) 9.6 % ( α = 0.05 ) . Primary objective : ass efficacy , dose , safety tolerability Y- shape pegylated interferon ( YPEG-IFNα-2a ) plus ribavirin Egyptian patient chronic hepatitis C prior treatment HCV . Secondary objective : To assess plasma level YPEG-IFNα-2a first 30 patient group , ensure therapeutic plasma level drug 2 hour , 6 hour , 10 hour , 24 hour , 3 day , 5 day , 7 day , 10 day , 14 day 28 day . Treatment strategy : Three group group include 100 patient . The first group treat : YPEG-IFN α-2a 180mcg/week 48 week . Ribavirin 15 mg/kg/day 48 week . The second group treat : YPEG-IFN α-2a 180mcg/10 day 48 week . Ribavirin 15 mg/kg/day 48 week . The third group treat : YPEG-IFN α-2a 180mcg/ 2 week 48 week . Ribavirin 15 mg/kg/day 48 week . HCV RNA PCR do 24 week negative PCR patient continue treatment another 24 week PCR positive patient consider non responder follow . Evaluation dose efficacy side effect obtain 4 week 12 week treatment , serious side effect significant dose difference early virological response group lead shift group dose 180 mcg/week . Main outcome : Viral clearance qualitative HCV RNA base PCR 24 week end treatment . Secondary outcome : Evaluation HCV RNA 12 24 week ; change HCV RNA load treatment ; normalization ALT treatment 24 week end treatment ; study side effect ; histological change 24 week end treatment : decrease least 1 point Metavir score .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Age &gt; 18 year &lt; 65 year Chronic hepatitis C define : HCV antibodies use third generation test ; HCVRNA positive PCR ; liver biopsy past 12 month ; METAVIR score A1 F0 high ALT &gt; 1 ULN 24 week prior inclusion ( W26 ; W2 ) Patients never treat ribavirin , Interferon PEGInterferon Normal albumin , prothrombin time &gt; 60 % ; normal bilirubin Alphafoetoprotein &lt; 3 time normal range laboratory reference HBs antigen negative Anti Bilharzial antibody positive rectal snip shall do . The examination may repeat praziquantel treatment positive test Hemoglobin &gt; 11g/dl , leucocytes &gt; 3000/mm3 , neutrophil &gt; 1500/mm3 , platelet &gt; 100 000/mm3 , blood creatinin &lt; 1.4 mg/dl Normal TSH ( subject need treatment maintain TSH within normal range may include eligibility criterion respect ) Antinuclear antibodies &lt; 1/160 Fasting blood sugar 70115mg/dl ; glucose intolerance diabetes , HbA1C &lt; 8.5 % Normal ophthalmologic examination patient history blood pressure and/or diabetes Effective contraception ( IUD , diaphragm spermicide , condom spermicide , oral contraceptive , progesterone implant ( Norplant ) , medroxyprogesterone acetate ( Depoprovera ) , tubal ligation , vasectomy ) treatment period female . No breastfeeding study period Signed informed consent Exclusion criteria Other liver disease associate chronic hepatitis C : coinfection hepatitis B ( positive HBs antigen ) ; hemochromatosis ; alpha1 antitrypsin deficiency ; Wilson disease ; alcoholismrelated liver disease ; Gilbert disease Alcohol intake &gt; 50g/day male 40 g/day female Ongoing intravenous drug use Aggravated liver cirrhosis : history presence ascitis , oesophageal varicosis , liver encephalopathy Hepatocellular carcinoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>pegylated interferon</keyword>
	<keyword>interferon</keyword>
	<keyword>HCV</keyword>
	<keyword>genotype 4</keyword>
</DOC>